HCC treated with immune checkpoint inhibitors: a hyper-enhanced rim on Sonazoid-CEUS Kupffer phase images is a predictor of tumor response.
In: European Radiology, Jg. 33 (2023-06-01), Heft 6, S. 4389-4400
Online
academicJournal
Zugriff:
Objectives: We aimed to evaluate the efficacy of anti-programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) antibody therapy by assessing the hyper-enhanced rim phenomenon of hepatocellular carcinoma (HCC) on Sonazoid-contrast-enhanced ultrasound (CEUS) Kupffer phase images. Methods: This retrospective study included 61 patients with HCC who received anti-PD-1/PD-L1 antibody therapy from August 1, 2020, to January 31, 2022. We compared the progression-free survival (PFS) of patients with hyper-enhanced rim+ and hyper-enhanced rim-nodules and the time to nodule progression (TTnP) of hyper-enhanced rim+ and hyper-enhanced rim− nodules. Results: Thirty-nine patients received postoperative therapy, and 22 patients had unresectable HCC. The mean PFS was 11.8 months (95% confidence interval [CI]: 8.7–14.9) for patients with hyper-enhanced rim+ HCC nodules and 16.5 months (95% CI: 14.9–18.1) for patients with hyper-enhanced rim- HCC nodules in the surgery group (p = 0.017). The mean PFS was 9.2 months (95% CI: 3.6–14.8) for patients with hyper-enhanced rim+ HCC nodules and 17.8 months (95% CI: 14.9–20.6) for patients with hyper-enhanced rim− HCC nodules in the non-surgery group (p = 0.015). For hyper-enhanced rim+ HCC nodules, TTnP for each nodule exceeding the specified threshold was 10.1 months, whereas that for hyper-enhanced rim− HCC nodules was 17.6 months (p = 0.018). The disease control rate was 42.9% (3/7) for hyper-enhanced rim+ HCC nodules and 85.7% (21/24) for hyper-enhanced rim− HCC nodules (p = 0.013). Conclusions: The presence of hyper-enhanced rim on the Kupffer phase images obtained via the non-invasive Sonazoid-CEUS is a promising imaging biomarker for predicting unfavorable response with anti-PD-1/PD-L1 therapy in patients with HCC. Key Points: • The mean progression-free survival was 11.8 months for patients with hyper-enhanced rim+ HCC nodules and 16.5 months for patients with hyper-enhanced rim- HCC nodules in the surgery group. • The mean progression-free survival was 9.2 months for patients with hyper-enhanced rim+ HCC nodules and 17.8 months for patients with hyper-enhanced rim- HCC nodules in the non-surgery group. • The disease control rate was 42.9% for hyper-enhanced rim+ HCC nodules and 85.7% for hyper-enhanced rim− HCC nodules (p = 0.013). [ABSTRACT FROM AUTHOR]
Titel: |
HCC treated with immune checkpoint inhibitors: a hyper-enhanced rim on Sonazoid-CEUS Kupffer phase images is a predictor of tumor response.
|
---|---|
Autor/in / Beteiligte Person: | Huang, Zhe ; Zhu, Rong-Hua ; Xin, Jun-Yi ; Li, Kai-Yan |
Link: | |
Zeitschrift: | European Radiology, Jg. 33 (2023-06-01), Heft 6, S. 4389-4400 |
Veröffentlichung: | 2023 |
Medientyp: | academicJournal |
ISSN: | 0938-7994 (print) |
DOI: | 10.1007/s00330-022-09339-5 |
Schlagwort: |
|
Sonstiges: |
|